Healthcare Due Diligence: HIPAA, Clinical Risk & Life Sciences

Healthcare targets sit at the intersection of clinical outcomes, regulated privacy, reimbursement rules, and fraud-and-abuse exposure. Healthcare due diligence decides whether revenue, growth, and margin claims survive contact with HIPAA posture, credentialing, quality metrics, payor contracts, coding samples, and (for life sciences) regulatory and evidence paths. It is not the same as generic regulatory diligence, data privacy diligence, financial diligence, or operational diligence. Healthcare diligence underwrites the care and reimbursement layer: who pays, who is protected, and what can reverse after close.

Healthcare vs regulatory vs privacy vs financial diligence

Six pillars of healthcare diligence

1. Entity map, licenses & clinical footprint

Map every legal entity, site of care, NPI, license, accreditation (e.g. Joint Commission, ACHC), and state-by-state authority to operate. Separate owned clinics, MSOs, affiliated practices, telehealth, labs, pharmacies, and pure software. Confirm who employs clinicians, who bills, and who holds medical decision-making. Tie footprint to growth plans and any certificate-of-need or corporate-practice-of-medicine constraints in target states.

2. HIPAA, PHI flows & vendor BAAs

Determine covered entity vs business associate status for each product and legal entity. Inventory PHI and ePHI systems: EHR, billing, CRM, analytics, AI copilots, support tools, and third-party subprocessors. Review BAAs, access controls, audit logs, encryption, breach history, OCR correspondence, and incident response. Connect findings to data privacy diligence and cybersecurity diligence — HIPAA is not a substitute for either, and neither replaces HIPAA.

3. Clinical quality, credentialing & patient safety

Review quality scores, adverse events, never events, complaint and grievance logs, peer review, infection control, and outcomes vs peers where public data exists. Confirm credentialing, privileging, and license verification for material providers. For digital health, map clinical protocols, human oversight, escalation paths, and whether claims of outcomes are measured. Quality failures become license, payor, and brand risk fast.

4. Payor mix, reimbursement & revenue quality

Break revenue by Medicare, Medicaid, commercial, Medicare Advantage, value-based care, cash-pay, and other. Stress rate schedules, renewals, prior authorization friction, denial and appeal rates, days in AR, and bad debt. Test concentration on a few payors or one geography. Align commercial claims with customer concentration diligence and working capital with working capital diligence. Growth that is only volume at declining unit rates is not the same as growth in economic quality.

5. Coding integrity, billing compliance & fraud/abuse

Sample coding and documentation for medical necessity, upcoding, unbundling, modifier use, and outlier utilization. Review internal audit findings, RAC/MAC/UPIC activity, self-disclosures, CIAs, and False Claims / Anti-Kickback / Stark exposure. Map referral relationships, marketing arrangements, and any financial ties to referral sources. Aggressive coding can inflate trailing EBITDA and reverse post-close.

6. Life sciences, devices & product regulatory path

For biotech, medtech, diagnostics, and digital therapeutics: map regulatory classification, clearances/approvals, clinical evidence, manufacturing/QMS, post-market surveillance, and remaining trial or submission risk. For pure software claims that touch clinical decisions, test whether the product is regulated as a medical device and whether marketing matches clearance. Tie IP and freedom-to-operate to IP diligence and product claims to product diligence.

Stage sequencing (IOI to close)

Red flags

Cost & timeline (traditional vs first-pass)

50-point healthcare diligence checklist

• Legal entity map tied to sites of care and NPIs
• State licenses and accreditations inventory current
• Corporate practice of medicine / MSO structure documented
• Who employs clinicians vs who bills clarified
• Telehealth multi-state licensing footprint mapped
• Covered entity vs business associate status per entity
• PHI and ePHI system inventory complete
• BAAs in place for material vendors and subprocessors
• Access control, audit log, and encryption posture reviewed
• Breach history and OCR correspondence reviewed
• Incident response and breach notification playbooks exist
• AI / analytics tools that touch PHI listed with BAAs
• Quality scores and peer benchmarks collected
• Adverse event, complaint, and grievance logs reviewed
• Credentialing and privileging process documented
• License verification for material providers sampled
• Clinical protocols and escalation paths for digital care mapped
• Payor mix by revenue and volume quantified
• Top payor contracts and rate schedules obtained
• Denial, appeal, and prior-auth metrics known
• Days in AR, bad debt, and collection trends reviewed
• Value-based care downside risk modeled
• Coding sample plan (CPT/HCPCS/ICD) defined
• Medical necessity and documentation quality sampled
• Modifier and unbundling risk assessed
• Internal audit / compliance program maturity reviewed
• RAC/MAC/UPIC or other audit history listed
• Self-disclosures, CIAs, settlements inventory complete
• Anti-Kickback / Stark / referral relationship map drafted
• Marketing and patient inducement practices reviewed
• Med-mal claims history and reserves summarized
• Insurance: professional liability, cyber, tail coverage checked
• Key clinical and revenue-cycle talent map and bus factor
• EHR and billing system ownership / contracts confirmed
• Data portability and conversion plan if systems change
• For life sciences: regulatory classification documented
• Clearances, approvals, and remaining submissions listed
• Clinical evidence quality and trial status reviewed
• QMS / manufacturing / post-market surveillance skim
• Software-as-medical-device risk assessed if applicable
• IP and freedom-to-operate skim for core products
• Customer concentration of health systems / payors known
• Competitive density and substitution risk framed
• SPA compliance and healthcare-specific rep topics listed
• Indemnity / escrow plan for known coding or OCR risks
• Day-1 access to EHR, billing, and compliance systems
• No silent coding or protocol change policy post-close
• Integration plan for multi-site credentialing and BAAs
• Kill criteria documented for clinical and reimbursement risks
• Public CMS / enforcement / quality sources cited where used

How deal teams use a first-pass pack

Before LOI, buyers use structured public research to pressure-test whether a healthcare story is underwritable: public quality and utilization data, enforcement and breach signals, clinical trial or clearance status, payor concentration hints from filings, competitive density, and whether growth claims match sector rate reality. After LOI, the same hypotheses drive the data-room request list — license map, BAA inventory, coding samples, payor contracts, quality logs, life sciences evidence — so advisors do not spend weeks on marketing slides. The pack is screening research, not a substitute for coding audits, OCR-ready privacy assessments, or medical-legal opinions.